AlphAIalphai — Financial news for AI agents
prnewswire.comJUL 243 min read$ADMA

ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS

Hagens Berman announced a securities fraud class action against ADMA Biologics, Inc. (NASDAQ: ADMA) for alleged misstatements about its financial condition, revenue recognition, inventory distribution, and business practices. The suit covers Aug. 9, 2024 to Mar. 25, 2026, with an Aug. 10, 2026 lead plaintiff deadline, alleging channel stuffing, related-party transactions, and weak internal controls.

Original reporting
prnewswire.com
Published Jul 24, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 12:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS — source image
Source · prnewswire.com
Decision brief

The 30-second read

$ADMABearishMed
01

Why it matters

If the allegations gain traction or align with prior investigative findings, ADMA could face increased litigation costs, potential settlements, and further investor skepticism around reporting quality and internal controls.

02

Market read

A newly filed, company-specific securities-fraud complaint can increase perceived downside risk and volatility for ADMA, especially given the accounting and internal-controls allegations.

03

What to watch

Traders should check whether the alleged corrective disclosures correspond to already-known events, and whether ADMA has issued a substantive response or any related SEC/regulatory updates not mentioned here.

Relevance 6/10Novelty 6/10Timing: today’s PRNewswire alert about a newly filed ADMA securities-fraud class action and lead-plaintiff deadline (Aug. 10, 2026)

Background

The piece is a plaintiffs’ law-firm alert stating a securities-fraud class action was filed against ADMA for alleged misrepresentations about financial condition, revenue recognition, inventory distribution, and business practices.

Company-level read

Ticker impact

$ADMABearishMedium confidence
Context

PRNewswire reports a securities-fraud class action against ADMA alleging misstatements on financial condition, revenue recognition, and internal controls.

Expected impact

Near-term bias to downside or volatility until investors assess materiality, any related regulatory findings, and company response.

Evidence & confidence

The article is a law-firm alert, but it is still a fresh, company-specific legal development alleging channel stuffing, related-party transactions, and weak internal controls.

Market effects

Sector

Could modestly increase perceived governance and accounting-risk scrutiny for biotech/distribution-adjacent public issuers, but no sector-wide regulator action is cited.

Regional

Primarily US-focused investor sentiment given NASDAQ listing and US securities-fraud framing.

Global

Limited, as the filing is US securities litigation with no cross-border regulatory or operational impact described.

Counterpoint

What could challenge this read

A complaint is an allegation, and absent new company admissions, the market may discount it relative to prior disclosures and focus on whether any corrective disclosures already occurred.

Key entities

  • public_company
    ADMA Biologics, Inc.

    NASDAQ-listed company named as the defendant in the securities-fraud class action described.

  • law_firm
    Hagens Berman

    Plaintiffs’ firm issuing the investor alert and soliciting participation; not a defendant.

  • person
    Reed Kathrein

    Partner leading the firm’s investigation per the article quote.

Read at source← All news

Related articles

AUG 5
$ADMAHigh

ADMA BIOLOGICS, INC. (ADMA): Results of Operations and Financial Condition

ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20079311_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year

SEC EDGAR 8-K4 min
AUG 4
$ADMAMed

ADMA Stock Drop: ADMA Biologics Channel Stuffing Allegations Lead to 29% Stock Drop and Securities Fraud Class Action for Investors

ADMA Biologics (NASDAQ:ADMA) faces a securities fraud class action after its shares fell about 29%, following Culper Research allegations of channel stuffing tied to reported 20% 2025 growth. The complaint cites potential violations of Sections 10(b) and 20(a). ADMA stock dropped from $13.59 (Mar 23, 2026) to $9.63 (Mar 25) after the report.

prnewswire.com4 min
JUL 28
$ADMAMed

ADMA Class Reminder: ADMA Biologics Investors are Reminded of the Upcoming August 10 Deadline in the Filed Securities Fraud Class Action to Recover Losses

Bleichmar Fonti & Auld LLP said a securities fraud class action was filed against ADMA Biologics (NASDAQ:ADMA) and executives, alleging federal securities law violations tied to Culper Research claims of channel stuffing. The suit cites a March 24, 2026 16.6% drop after a report alleging undisclosed related-party distributor activity. Investors have until Aug. 10, 2026 to seek lead-plaintiff status.

prnewswire.com3 min
JUL 21
$ADMAMed

ADMA Lawsuit Notice: ADMA Biologics Channel Stuffing Allegations and 29% Stock Drop Trigger Securities Fraud Class Action

Bleichmar Fonti & Auld LLP says it filed a securities fraud class action against ADMA Biologics (NASDAQ:ADMA) and executives after ADMA shares fell about 29% following Culper Research’s channel-stuffing allegations tied to reported 20% 2025 growth and ASCENIV. The complaint cites Sections 10(b) and 20(a) and names Mazzarino v. ADMA Biologics, No. 26-cv-6918, with an Aug. 10, 2026 lead-plaintiff deadline.

prnewswire.com4 min
JUL 1
$ADMAMedAI 8/10

Kessler Topaz Meltzer & Check said a securities-fraud class action was filed against ADMA Biologics (NASDAQ: ADMA)

Kessler Topaz Meltzer & Check said a securities-fraud class action was filed against ADMA Biologics (NASDAQ: ADMA) in the District of New Jersey for purchases between Aug. 9, 2024 and Mar. 25, 2026. Allegations include undisclosed related-party transactions, channel stuffing, and weak internal controls. The firm cites a March 24 Culper Research report tied to a 29.1% stock drop on Mar. 25. Lead plaintiff deadline: Aug. 10, 2026.

stockhouse.com4 min
JUN 1
$ADMAMedAI 8/10

ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCENIV

The article claims ADMA Biologics received an FDA label expansion for its ASCENIV product, but it provides no additional details or figures. The rest is promotional content for an “Insider Monkey” newsletter, citing broad AI/robotics themes and alleging a prior stock call (British American Tobacco) returned 90% in 16 months.

insidermonkey.com2 min